Results 151 to 160 of about 3,345,719 (364)
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai +28 more
wiley +1 more source
Thrombotic Thrombocytopenic Purpura, Moschcowitz Syndrome [PDF]
The authors present a case of a 16-year-old boy, who was referred to the hospital due to thrombocytopenia, anemia, proteinuria and hyperbilirubinemia. Based on the clinical picture and the laboratory data, thrombotic thrombocytopenic purpura (TTP) was ...
Czinyéri, Judit +4 more
core
ABSTRACT Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole‐exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G>A (
Akihiko Mitsutake +12 more
wiley +1 more source
The Necessity of Upper Extremity Neurologic Examination while Evaluating Breast Pain. [PDF]
Belli AK +8 more
europepmc +1 more source
The influence of neurological examination timing within hours after acute traumatic spinal cord injuries: an observational study [PDF]
Nathan Evaniew +13 more
openalex +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Introduction to Clinical Examination for Physical Therapy Treatment: V. Neurological Disorders.
Mari KUNII, Mieko Kurosawa
openalex +2 more sources
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
BrainWave Diagnostics: An Extensive Examination of Determinants of Multiple Neurological Disease from EEG Signals [PDF]
Shraddha Jain
openalex +1 more source

